Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Stock Watcher who wrote (40579)	11/8/2000 7:49:13 AM
From: StocksDATsoar	Read Replies (1) \| Respond to of 52051

HUGE NEWS FOR IFOS SW....DEFINITELY NOT A BUY RECO ON IFOS. otcnn.com IFS Takes Polystyrene Recycling System to Norway By Peter Lim Published by OTCNN.com 11/06/2000 09:26 AM EST International Foam Solutions, Inc. (IFS) (OTCBB: IFOS) is finalizing an agreement with Arcon AS, a distributor of raw materials to the Norwegian industry, to represent IFS and be the exclusive distributor in Norway for IFS and sell IFS’s polystyrene recycling system, Styro Solve and Solution Machine. The dollar value of the contract was not disclosed. Styro Solve is a chemical solution while the Solution Machine is a device, of various sizes, that facilitates the process of recycling polystyrene. Recycled polystyrene can be used in the manufacture of products ranging from videocassettes, cameras, plastic razor handles, chemical pencils and computer cases. After engaging in research and development for seven to eight years, IFS only recently took its product to market. The pending Norwegian deal is IFS’s second foray into a foreign market; Japan is its first. “Being quite honest, the European base and the European countries have stronger regulations on recycling than the US,” IFS CEO, Harvey Katz told OTCNN. “And because of the strong regulations and the strong requirements that they have on recycling, this turns out to be a very good mix for IFS and distributors like Arcon.” According to IFS, there are 17-19 million fish boxes being produced in Norway and over 1,000 metric tons of polystyrene used in making yogurt containers alone. Headquartered in Delray Beach, FL, IFS hopes the Norwegian deal represents the first in a series of European companies to enter into contracts with the company and that the deal will trigger a domino effect. Katz is currently involved in definitive discussions with companies in Denmark, Finland and Sweden, formalizing negotiations with companies in Germany and Italy and engaged ongoing negotiations with companies in England, France and Belgium. “The Scandinavian market is a very, very strong market at this time,” Katz said. “On my last trip I discovered that (among) all of the European countries, the first environmental ideas, concepts and projects seem to start up in the Scandinavian countries, then go to Germany and Italy and then they come into France, Belgium and England.” On the domestic front, IFS’s recycling system, despite only recently hitting the market, has already been well received by a handful of entities, Katz said. Among its American clients are the Albany and Bakersfield school districts and the City of Los Angeles Power and Water Department, he added. Established in 1993, IFS has been a public traded company since Sept. 1997. Now that the company has completed its R&D and is in “full force marketing,” Katz expects a better performance of its stock and an imminent departure from the OTCBB. The stock closed at $0.20 on Friday, up 11 percent, after trading 141,700 shares. Disclaimer OTC News Network is an unbiased, objective news source focusing exclusively on OTC Bulletin Board companies. We do NOT publish any paid editorial content. In addition, OTC News Network does NOT own any stock in any OTC Bulletin Board companies. None of the shareholders, officers and affiliated entities owns any stock in the companies mentioned in this article. This ensures that OTCNN can make its editorial decisions objectively. Companies included in the news stories have NOT paid a fee or any other form of compensation for their appearance.

To: Stock Watcher who wrote (40579)	11/8/2000 8:20:46 AM
From: StocksDATsoar	Respond to of 52051

DNAP Wednesday November 8, 7:08 am Eastern STD Press Release DNAPrint Announces Pharmacogenomics Collaboration SARASOTA, Fla. & JACKSONVILLE, Fla.--(BUSINESS WIRE)--Nov. 8, 2000--DNAPrint genomics, Inc. (Pink Sheets:DNAP) announced today that the company has partnered with a group of independent physicians of internal family medicine in the Jacksonville, Florida area to conduct original research in order to discover and develop new personalized medical products. The products produced through the collaboration could be used in the near future to genetically match hypercholesterolemic and dyslipidemic patients with optimal chemotherapy regimens. Specific terms of the agreement were not disclosed. Hypercholesterolemic and dyslipidemic patients are at increased risk for atherosclerotic vascular (heart) disease. Currently, these patients are prescribed medications, nicknamed ``statins'', to ameliorate this risk. Statins function to decrease cholesterol levels by inhibiting a key enzyme (HMG-Co enzyme A reductase) in the cholesterol pathway. According to the National Heart, Lung, and Blood Institute's National Cholesterol Education Program, high cholesterol is one of the key risk factors for heart disease. Heart disease is the number one cause of death for both men and women in the United States, and more than 90 million American adults, or about 50 percent of the population, have elevated blood cholesterol levels. A study published in the New England Journal of Medicine in September 1998 says heart disease deaths have declined steadily over the last 30 years, decreasing by 10.3 percent between 1990 and 1994 alone. This improvement is largely attributable to better prevention of heart disease through the wide-spread use of statins. Notwithstanding the efficacy of this class of drugs, individual patients respond differently to statins based on a variety of inter-individual genetic and environmental differences. About 2%-5% of patients are discontinued from statin treatment due to adverse experiences including hepatocellular toxicity (indicated by elevated serum levels of certain liver enzymes), and more rarely, Rhabdomyolysis with acute renal failure. In fact, it is recommended that physicians monitor this toxicity by performing liver function tests prior to, and at 12 weeks following, both the initiation of therapy and any elevation of dose, and periodically thereafter. As a recent Time magazine article points out, statins may potentially serve as a useful preventative tool to reduce the risk of heart disease in the general, healthy population. A key impediment for the expansion of the statin market in this way is the danger posed by adverse events associated with use of these drugs. For example, the long term affects of hepatocellular injury is not clearly understood. Diagnomics products could potentially help reduce the risk associated with the use of statins in the general population. The project announced today is expected to result in a ``diagnomics'' test solution for routine patient pre-screening prior to statin prescription. Based on the prevalence of dyslipidemia and hypercholesteremia in the population, such a product could enjoy a market in excess of several billion dollars in the near future. The specific aims of the collaboration are to qualify and quantify the genetic and environmental determinants underlying variation of hypercholesterolemic and dyslipidemic patient response to statin chemotherapy. The collaboration will provide DNAPrint the unique opportunity to explore the connection between human genetic variation (polymorphism), environment, and treatment response using a rare combination of resources, including a heavily annotated and consent-qualified specimen databank, prospective and retrospective patient tracking, state-of-the-art automated genomics equipment and proprietary analytics for complex genetics. Under the terms of the agreement a group of Jacksonville physicians will supply consent qualified, biographed and annotated patient specimens as well as prospective and retrospective patient disease and treatment data. DNAprint genomics will perform the background variability discovery, high-throughput genotyping and complex genetic analysis. Dr. Elyssa A. Bissenbach, M.D., P.A. will serve as the chief physician for the project. Dr. Bissenbach has prior research experience at SUNY and is board certified in Internal Medicine. Also joining the project are Dr. Reuben Louis Smith and Dr. Richard Flynn, who together have a combined patient census of 20,000 individuals, 35% of whom are dyslipidemic and/or hypercholesterolemic. Robert Preston White, PA-C, will serve as primary coordinator and principal investigator for the study. Mr White has previous experience managing complex specimen collections, having performed similar work with N.I.H. funded collections at the University of Miami School of Medicine and Mt. Sinai Medical Center in Miami Beach, FL. ``Critics of preventative coronary medicine for the general healthy population often, and rightly, invoke unacceptable risk vs. reward levels associated with the use of drugs such as Statins,'' said Tony Frudakis, Ph.D., CEO/CSO of DNAprint genomics, Inc. ``Only through progress in the area of complex pharmacogenomics is it logical to contemplate an era of rational and safe preventative medicine involving this class of drugs.'' DNAPrint genomics, Inc. is developing complex genetic analytics and information resources for next generations personalized medicine. The companies products will provide practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. For more information about the company, please visit www.dnaprint.com All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. -------------------------------------------------------------------------------- Contact: DNAPrint genomics, Inc., Sarasota For Scientific inquiries: Tony Frudakis, Ph.D., 941/351-4543 or Other inquiries Richard Craig Hall, 941/341-0136

To: Stock Watcher who wrote (40579)	11/8/2000 8:42:57 AM
From: mike.com	Read Replies (1) \| Respond to of 52051

Things are beginning to heat up for IATV: "Wednesday November 8, 8:18 am Eastern Time Press Release Grey Global Group Joins ACTV's Digital ADCO for SpotOn, Addressable Interactive TV Advertising ITV Ad Service with Full-Motion Video is Compatible with Currently Deployed Digital Set-Tops NEW YORK--(BUSINESS WIRE)--Nov. 8, 2000-- ACTV, Inc. (NASDAQ: IATV - news) today announced that MediaCom, Grey Global Group's (NASDAQ: GREY - news) media service partner, will work with ACTV on the development of addressable television messaging via SpotOn(sm). SpotOn, a service of ACTV subsidiary Digital ADCO, Inc., is the leading end-to-end, software-based and TV-centric system that enables the delivery and accounting of highly targeted and interactive TV advertising, featuring full-motion video. SpotOn is compatible with all of the leading digital interactive platforms and set-top terminals, including those currently deployed. Grey Global Group (NASDAQ: GREY - news) is a leading marketing services company whose partner companies include MediaCom, Grey Worldwide and Grey Direct. ``With SpotOn, we can use much of the content that already exists, and apply these new, exciting addressable and interactive marketing utilities on top of what already has proven to be popular content: today's traditional TV product,'' said Alec Gerster, Chairman, MediaCom. In contrast to other new technologies that allow viewers to zap out TV commercials, the SpotOn service focuses on making TV advertising more meaningful and useful for viewers. SpotOn is designed to deliver targeted commercials based on viewers' interests, allowing them to see ads that are truly relevant while providing access to value-added information and special offers from the advertisers. The goal of SpotOn is to dramatically improve the effectiveness of TV advertising and, for the first time, bring real accountability to an advertiser's media buy. SpotOn can be delivered via digital cable, digital satellite, or digital broadcast television. ``We are excited about the potential represented by SpotOn,'' said Russ Booth of MediaCom. ``If we can allocate our messages precisely, we expect our clients will have a greater return on the value of their advertising expenditures. Even the simplest segmentation can have dramatic results.'' ``MediaCom was one of the first agencies to explore the value of true interactive TV,'' said Art Cohen, Senior Vice President of Advertising and E-commerce, ACTV, Inc. ``We look forward to collaborating with them as we introduce SpotOn and believe our joint efforts will help shape the future of television advertising.'' About SpotOn(sm) ACTV created its Digital ADCO subsidiary with Motorola Broadband Communications Sector to redefine traditional TV advertising. SpotOn is founded on an array of system technologies, including ACTV's patented One To One TV(sm) software and Motorola's digital interactive platform. ACTV, Motorola and OpenTV (Nasdaq and AEX: OPTV) recently joined forces for the international deployment of SpotOn. SpotOn allows viewers to choose and interact with television commercials; it empowers advertisers to deliver commercials to households most likely to respond to them; and it allows television network operators to generate new advertising and TV commerce revenues. SpotOn services are provided to cable and satellite system providers, advertising interconnects, broadcast and cable television networks and programmers, and leading consumer product advertisers, advertising agencies, and media buyers. For more information, visit spoton.tv. About ACTV, Inc. ACTV, Inc. (Nasdaq: IATV - news), with headquarters in New York City, pioneered enhanced media with its patented convergence technology, which it markets under the brand name HyperTV® (http://www.hypertv.com). The company also created interactive one-to-one digital television with its proprietary One To One TV software and programming capabilities. SpotOn, the advertising application of One To One TV, is a service of ACTV subsidiary Digital ADCO, Inc. ACTV has developed an extensive patent portfolio that broadly covers the core methodologies for enhancing television, radio and other audio visual programming with an array of synchronous and non-synchronous Internet-based functions, and for the creation and delivery of interactive, one-to-one digital television. ACTV has key strategic relationships with many of the dominant players in the Internet, television and digital technology fields, including Liberty Digital, Inc. (Nasdaq: LDIG - news), Motorola (NYSE: MOT - news) Broadband Communications Sector, OpenTV (Nasdaq and AEX: OPTV), and Liberty Livewire Corporation (Nasdaq: LWIRA - news). For more information, visit actv.com. About Grey Global Group Grey Global Group, with over $9 billion in annual billings, ranks among the largest global marketing communications companies in the world. Grey Global Group operates branded independent partner companies in many Communications specialties including public relations/public affairs, direct marketing, Internet communications, healthcare marketing, and on-line and off-line media services. Grey Worldwide, the core advertising agency, with 408 offices in 90 countries around the world, ranks among the top ten advertising agencies in the world and is ranked as the largest advertising agency in the United States. This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements which are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the companies, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the companies disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. -------------------------------------------------------------------------------- Contact: For ACTV, Inc: Bratskeir & Company Mike Rosen, 212/679-2233 (ACTV Media Relations) mrosen@bratskeir.com or Brainerd Communicators Kim Holt, 212/986-6667 (Financial Media) holt@braincomm.com or ACTV, Inc. Bill Roll, 212/217-1600 wroll@actv.com or For MediaCom: Steve Ellwanger, 203/291-6986 mediasteve@pop.snet.net or For Grey Global Group: Jan Sneed, 212/546-2422 jsneed@grey.com" biz.yahoo.com